KLRS

Kalaris Therapeutics, Inc. KLRS

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$73.41M total
Samsara BioCapital, LLC
$52.43M-0.5%
RTW INVESTMENTS, LP
$5.29M0.0%
Alyeska Investment Group, L.P.
$2.33M0.0%
Siren, L.L.C.
$1.77M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$1.62M+56.1%
Ikarian Capital, LLC
$1.47M0.0%
UBS Group AG
$1.07M+4138.9%
RENAISSANCE TECHNOLOGIES LLC
$607.9K+125.8%
MARSHALL WACE, LLP
$566.5K+105.1%
GEODE CAPITAL MANAGEMENT, LLC
$464.3K+30.3%
Woodline Partners LP
$407.0K0.0%
ADAR1 Capital Management, LLC
$407.0K0.0%
WHI TRUST Co LLC
$396.8K0.0%
RAYMOND JAMES FINANCIAL INC
$395.5K-18.3%
CITADEL ADVISORS LLC
$389.8KNew
BOOTHBAY FUND MANAGEMENT, LLC
$375.5K0.0%
Verdad Advisers, LP
$326.8KNew
MORGAN STANLEY
$294.4K+88.6%
VANGUARD FIDUCIARY TRUST CO
$269.3K+80.2%
BlackRock, Inc.
$221.6K+51.0%
Belpointe Asset Management LLC
$162.8K0.0%
Fortis Capital Advisors, LLC
$162.8K0.0%
Pale Fire Capital SE
$161.3KNew
Squarepoint Ops LLC
$157.8K-2.5%
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$132.3K+44.4%
See all 57 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/KLRS

Earnings Per Share

13fpro.ai/company/KLRS

Loading ratio trend…

KLRS key financials by period

Reported revenue, net income and operating margin by fiscal year, from Kalaris Therapeutics, Inc.'s annual filings on SEC EDGAR.

Kalaris Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2019$165.0K$-23.8M—
Source: KLRS filings on SEC EDGAR →

KLRS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Kalaris Therapeutics, Inc. (KLRS): stock profile, AI score and financials

Kalaris Therapeutics, Inc. (KLRS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. KLRS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of KLRS by reported 13-F value include Samsara BioCapital, RTW INVESTMENTS, Alyeska Investment Group, L.P., based on the most recent SEC filings. KLRS trades on the Nasdaq exchange and files with the SEC under CIK 1754068. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KLRS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kalaris Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1754068 →